Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) presented Phase 3 RAPIDe-3 and Phase 2 CHAPTER-1 data at AAAAI 2026 supporting deucrictibant for on‑demand and prophylactic treatment of bradykinin‑mediated angioedema.
RAPIDe-3 met the primary and all 11 secondary endpoints: median onset of symptom relief 1.28 hours and complete resolution 11.95 hours versus much longer placebo times. CHAPTER-1 OLE showed mean attack rate fell from 2.18 to 0.12 attacks/month and roughly half of participants were attack free; no treatment‑related serious adverse events reported.
Positive
- RAPIDe-3 met primary and all 11 secondary endpoints
- Onset of symptom relief in 1.28 hours
- Median complete symptom resolution in 11.95 hours
- Mean attack rate reduced from 2.18 to 0.12 attacks/month
Negative
- CHAPTER-1 final analysis was an open‑label extension (non-randomized)
News Market Reaction – PHVS
On the day this news was published, PHVS declined 1.37%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PHVS gained 1.39% with modestly positive biotech peers (e.g., BHVN +4.82%, EWTX +3.03%, MNKD +4.13%). Momentum scanner only flagged 1 peer (VRDN, down 10.18%), suggesting the move was stock-specific rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Conference preview | Positive | +1.7% | Announced six abstracts for AAAAI 2026, including pivotal RAPIDe-3 and CHAPTER-1. |
| Jan 12 | Strategy update | Positive | +0.8% | Outlined 2026 priorities, NDA timing, pivotal data expectations, and cash runway into 1H2027. |
| Dec 03 | Pivotal trial topline | Positive | +21.8% | Reported RAPIDe-3 Phase 3 success with rapid symptom relief and full endpoint success. |
| Nov 12 | Earnings and pipeline | Positive | +7.0% | Q3 2025 results plus progress on RAPIDe-3, CHAPTER-3, CREAATE, and financing. |
| Nov 10 | Conference data | Positive | +4.8% | Presented long-term CHAPTER-1 efficacy, RAPIDe-2 data, and kinin biomarker assay at ACAAI. |
Recent clinically focused and corporate updates have all coincided with positive 24-hour price reactions, indicating a pattern of constructive market response to deucrictibant milestones.
Over the past six months, Pharvaris has repeatedly highlighted late-stage development of deucrictibant. Positive RAPIDe-3 topline data on Dec 03, 2025 drove a 21.75% move, followed by earnings and strategy updates in November 2025 and January 2026, each with smaller gains. Conference presentations at ACAAI 2025 and AAAAI 2026 continued to showcase strong on‑demand and prophylactic HAE data, with all five tracked announcements yielding positive next‑day price reactions.
Market Pulse Summary
This announcement consolidates pivotal RAPIDe-3 results and long-term CHAPTER-1 data, emphasizing rapid symptom relief, durable attack reduction, and once-daily prophylactic potential for deucrictibant. Investors may compare these outcomes with prior ACAAI and strategic updates highlighting similar metrics such as attack rates of 0.12 attacks/month. Key risks include future Phase 3 readouts, regulatory review outcomes, and capital needs disclosed in past filings. Tracking additional efficacy, safety, and duration data will be important.
Key Terms
bradykinin-mediated angioedema medical
hereditary angioedema medical
acquired angioedema due to C1 inhibitor deficiency medical
bradykinin b2 receptor antagonists medical
immediate-release capsule technical
extended-release tablet technical
open-label extension medical
pharmacokinetic profile medical
AI-generated analysis. Not financial advice.
- RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and confirming its potentially differentiated profile for the treatment of HAE attacks
- Final CHAPTER-1 data provide further evidence on long-term safety and efficacy of deucrictibant for the prevention of HAE attacks; single-dose, sustained therapeutic exposure with deucrictibant extended-release tablet supports once-daily prophylactic application
ZUG, Switzerland, March 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations for the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, which took place from February 27-March 2, 2026, in Philadelphia, PA.
“The RAPIDe-3 data confirm the robust and consistent clinical effects of deucrictibant across our primary and all 11 secondary efficacy endpoints versus placebo, confirming its potentially differentiated profile for the treatment of all types of HAE attacks,” said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris. “Due to its mechanism of action, deucrictibant is expected to outcompete bradykinin at the B2 receptor, resulting in direct modulation of bradykinin signaling, as demonstrated by the rapid and sustained symptom relief and attack resolution findings from RAPIDe-3. We are pleased to present these pivotal data at AAAAI and look forward to future exchanges with the HAE community about deucrictibant’s potential to become standard of care in the treatment of HAE attacks.”
Details of the presentations are outlined below:
On-Demand Therapy
Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Study, presented by Marc A. Riedl, M.D., M.S. in a featured poster. The RAPIDe-3 (NCT06343779) global Phase 3, placebo-controlled study evaluated orally administered deucrictibant immediate-release capsule (20 mg) for the on-demand treatment of attacks in participants 12 years and older with HAE, including those with HAE with normal C1 inhibitor. Final results from RAPIDe-3 provide further evidence on the rapid and sustained efficacy, safety, and tolerability of deucrictibant. Results from this study met the primary and all 11 secondary efficacy endpoints. The median time to onset of symptom relief, the primary endpoint, was 1.28 hours with deucrictibant treatment versus over 12 hours with placebo. This endpoint was achieved by 12 hours in
Content Validity of the Angioedema symptom Rating scAle (AMRA) to Assess Symptoms of Hereditary Angioedema Attacks, presented by Teresa Caballero, M.D., Ph.D. A collated analyses from a mixed-methods study and RAPIDe-3 provided confirmatory evidence to support the validity of AMRA-3 and AMRA-5 in assessing the severity of key symptoms associated with HAE attacks. Participants across age groups, including adolescents and adults, reported a variety of symptoms when experiencing HAE attacks, with the most frequently observed symptoms captured by the AMRA-3 scale or, for people experiencing upper airway attacks, including laryngeal attacks, by the AMRA-5 scale.
Long-Term Prophylaxis
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study, presented by John Anderson, M.D. in a featured poster. Data from the final analysis of the open-label extension (OLE) of the two-part Phase 2 clinical study of deucrictibant for the long-term prophylaxis of HAE attacks, CHAPTER-1, provided further evidence about deucrictibant’s profile being well tolerated with no safety signals observed in the OLE for up to approximately three years; mean systolic and diastolic blood pressure remained stable throughout all study assessments. The attack rate reduced within one week of deucrictibant treatment remained low for up to approximately three years: the mean attack rate was reduced from a study baseline of 2.18 attacks/month to 0.12 attacks/month in the open-label extension. Additionally, approximately half of the participants in the open-label extension were attack free.
Long-Term Prophylactic Treatment With Oral Deucrictibant Improved Health-Related Quality of Life in Participants With Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study, presented by Michael E. Manning, M.D. Data from the final analysis of the open-label extension (OLE) of the two-part Phase 2 clinical study of deucrictibant for the long-term prophylaxis of HAE attacks, CHAPTER-1, showed that treatment with deucrictibant resulted in clinically-meaningful improvements in health-related quality of life (HRQoL) and disease control and in higher treatment satisfaction for up to approximately three years.
Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks, presented by Zhi-Yi Zhang, Ph.D. in a featured poster. Phase 1 data supporting the once-daily applicability of deucrictibant extended-release tablet include its single-dose pharmacokinetic profile under fasted and fed conditions and the sustained (≥24 hours) therapeutic exposure during repeat dosing.
Beyond HAE
A Novel Kinin Biomarker Assay for Characterization of Different Types of Bradykinin-Mediated Angioedema, presented by Evangelia Pardali, Ph.D. Pharvaris has developed an assay that can measure the levels of bradykinin and other kinin related peptides in plasma to characterize people with bradykinin-mediated angioedema. In addition to clearly showing bradykinin-forming cascade sensitivity in people with multiple types of HAE and with AAE-C1INH, cold activation caused increased bradykinin levels in samples from individuals with HAE with normal C1 inhibitor of unknown aetiology and angioedema of unknown cause, indication that the angioedema attacks in these individuals may be bradykinin-mediated. The clinically validated kinin biomarker assay may become a key tool for identifying, studying, and managing bradykinin-mediated diseases, including bradykinin-mediated angioedema.
About Deucrictibant
Deucrictibant is a novel, potent, orally bioavailable small-molecule bradykinin B2 receptor antagonist currently in clinical development. Deucrictibant is being investigated for its potential to prevent the occurrence of bradykinin-mediated angioedema attacks and to treat the manifestations of attacks if/when they occur by inhibiting bradykinin signaling through the bradykinin B2 receptor. Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable sustained absorption and efficacy as prophylactic treatment, and an immediate-release capsule to enable rapid onset of activity for on-demand treatment. Deucrictibant has been granted orphan drug designation for the treatment of bradykinin-mediated angioedema by the U.S. Food and Drug Administration, the European Commission, and Swissmedic.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/.
Forward Looking Statements
This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to our future plans, studies and trials, and any statements containing the words “believe,” “anticipate,” “expect,” “estimate,” “may,” “could,” “should,” “would,” “will,” “intend” and similar expressions. These forward-looking statements are based on management’s current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris’ actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: uncertainty in the outcome of our interactions with regulatory authorities, including the FDA; the expected timing, progress, or success of our clinical development programs, especially for deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials; our ability to replicate the efficacy and safety demonstrated in the RAPIDe-1, RAPIDe-2, RAPIDe-3, and CHAPTER-1 Phase 2 and Phase 3 studies in ongoing and future nonclinical studies and clinical trials, such as CHAPTER-3, and CREAATE; the timing and outcome of regulatory approvals, including the timing and outcome of our planned submission of an NDA with the FDA in the first half of 2026 for the on-demand treatment of acute attacks of HAE; risks arising from epidemic diseases, which may adversely impact our business, nonclinical studies, and clinical trials; our ability to potentially use deucrictibant for alternative purposes, for example to treat C1-INH deficiency (AAE-C1INH); the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry, including with respect to existing therapies, emerging potentially competitive therapies and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to produce sufficient amounts of drug product candidates for commercialization; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws (including the Biosecure Act), our ability to maintain an effective system of internal control over financial reporting; changes and uncertainty in general market conditions; disruptions at the FDA and other agencies; changes and uncertainty in general market, political and economic conditions, including as a result of inflation and geopolitical conflicts; changes in regulations and customs, tariffs and trade barriers; and the other factors described under the headings “Cautionary Statement Regarding Forward-Looking Statements” and “Item 3. Key Information—D. Risk Factors” in our Annual Report on Form 20-F and other periodic filings with the U.S. Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris’ views as of any date subsequent to the date of this press release.
Contact
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com
FAQ
What were the key RAPIDe-3 results for Pharvaris (PHVS) at AAAAI 2026?
How did deucrictibant affect attack frequency in PHVS CHAPTER-1 long-term data?
What safety findings did Pharvaris (PHVS) report for deucrictibant in the trials?
Does Pharvaris (PHVS) support once‑daily prophylaxis with deucrictibant extended‑release?
What types of hereditary angioedema were included in the PHVS RAPIDe-3 study?
